Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit
October 05 2016 - 6:00AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome
editing company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, announced that Chief
Medical Officer John Leonard, M.D., will participate in a panel
discussion and present a company overview at the Jefferies Gene
Editing/Therapy Summit on Tuesday, October 11, 2016.
Details of the presentation are as follows:
Jefferies Gene Editing/Therapy SummitDate:
Tuesday, October 11, 2016 Location: New York, New YorkTimes: Panel
discussion at 10:00 am ET with company presentation to follow at
2:00 pm ET.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatx.com
Investor Contacts:
John Graziano
Trout Group
+1 646-378-2942
jgraziano@troutgroup.com
Chad Rubin
Trout Group
+1 646-378-2947
crubin@troutgroup.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2024 to May 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From May 2023 to May 2024